200 related articles for article (PubMed ID: 30220224)
1. Preserving quality of life as a key treatment goal in advanced soft tissue sarcomas.
Jones RL; Le Cesne A; Ibrahim T; Garcia Del Muro X; Menge F
Expert Rev Anticancer Ther; 2018 Dec; 18(12):1241-1248. PubMed ID: 30220224
[TBL] [Abstract][Full Text] [Related]
2. Trabectedin for Advanced Soft Tissue Sarcoma: Ten Year Real-Life Perspective.
Shamai S; Merimsky O
Isr Med Assoc J; 2018 Oct; 20(10):599-603. PubMed ID: 30324774
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
[TBL] [Abstract][Full Text] [Related]
4. Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma.
de Sande González LM; Martin-Broto J; Kasper B; Blay JY; Le Cesne A
Expert Rev Anticancer Ther; 2020 Nov; 20(11):957-963. PubMed ID: 32930637
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
Jones RL; Demetri GD; Schuetze SM; Milhem M; Elias A; Van Tine BA; Hamm J; McCarthy S; Wang G; Parekh T; Knoblauch R; Hensley ML; Maki RG; Patel S; von Mehren M
Ann Oncol; 2018 Sep; 29(9):1995-2002. PubMed ID: 30084934
[TBL] [Abstract][Full Text] [Related]
6. Trabectedin use in soft-tissue sarcoma patients in a real-world setting: Data from an Italian national drug-access registry.
Vincenzi B; Napolitano A; Comandone A; Sanfilippo R; Celant S; Olimpieri PP; Di Segni S; Russo P; Casali PG
Int J Cancer; 2023 Feb; 152(4):761-768. PubMed ID: 36196483
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Trabectedin in Patients with Advanced Translocation-Related Sarcomas: Pooled Analysis of Two Phase II Studies.
Takahashi M; Takahashi S; Araki N; Sugiura H; Ueda T; Yonemoto T; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Shimura M; Kawai A
Oncologist; 2017 Aug; 22(8):979-988. PubMed ID: 28526720
[TBL] [Abstract][Full Text] [Related]
8. Experience with second-line trabectedin in daily clinical practice: case studies.
Martín-Broto J; Hindi N; Grignani G; Merlini A; Ibrahim T; Le Cesne A
Future Oncol; 2022 Sep; 18(30s):23-32. PubMed ID: 36200932
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.
Samuels BL; Chawla S; Patel S; von Mehren M; Hamm J; Kaiser PE; Schuetze S; Li J; Aymes A; Demetri GD
Ann Oncol; 2013 Jun; 24(6):1703-9. PubMed ID: 23385197
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical Trial.
Sanfilippo R; Hindi N; Cruz Jurado J; Blay JY; Lopez-Pousa A; Italiano A; Alvarez R; Gutierrez A; Rincón-Perez I; Sangalli C; Pérez Aguiar JL; Romero J; Morosi C; Sunyach MP; Fabbroni C; Romagosa C; Ranchere-Vince D; Dei Tos AP; Casali PG; Martin-Broto J; Gronchi A
JAMA Oncol; 2023 May; 9(5):656-663. PubMed ID: 36995731
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of trabectedin for the treatment of liposarcoma.
Zijoo R; von Mehren M
Expert Opin Pharmacother; 2016 Oct; 17(14):1953-62. PubMed ID: 27615729
[TBL] [Abstract][Full Text] [Related]
12. Real-World Experience of Efficacy and Safety of Trabectedin in Patients with Soft Tissue Sarcoma: A Bicentric Retrospective Analysis.
Chaigneau L; Jary M; Nerich V; Hervieu A; Aubry S; Charon Barra C; Meynard G; Neumann F; Kalbacher E; Isambert N
Oncology; 2022; 100(12):633-644. PubMed ID: 36283345
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin.
Jones RL; Maki RG; Patel SR; Wang G; McGowan TA; Shalaby WS; Knoblauch RE; von Mehren M; Demetri GD
Cancer; 2019 Dec; 125(24):4435-4441. PubMed ID: 31503332
[TBL] [Abstract][Full Text] [Related]
14. The intriguing patterns of tumor response to trabectedin.
Sanfilippo R; Casali PG
Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):21-4. PubMed ID: 23638727
[TBL] [Abstract][Full Text] [Related]
15. The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia.
Schack LH; Mouritsen LS; Elowsson C; Krarup-Hansen A; Safwat A
Acta Oncol; 2015 Jan; 54(1):34-40. PubMed ID: 25263179
[TBL] [Abstract][Full Text] [Related]
16. Retrospective Analysis of Trabectedin Therapy for Soft Tissue Sarcoma.
Kawaguchi K; Nakano K; Urasaki T; Fukuda N; Taira S; Ono M; Tomomatsu J; Nishizawa M; Ae K; Matsumoto S; Takahashi S
In Vivo; 2019; 33(5):1609-1614. PubMed ID: 31471412
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma.
Assi T; Kattan J; El Rassy E; Honore C; Dumont S; Mir O; Le Cesne A
Cancer Treat Rev; 2019 Jan; 72():37-44. PubMed ID: 30468937
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.
Grosso F; Jones RL; Demetri GD; Judson IR; Blay JY; Le Cesne A; Sanfilippo R; Casieri P; Collini P; Dileo P; Spreafico C; Stacchiotti S; Tamborini E; Tercero JC; Jimeno J; D'Incalci M; Gronchi A; Fletcher JA; Pilotti S; Casali PG
Lancet Oncol; 2007 Jul; 8(7):595-602. PubMed ID: 17586092
[TBL] [Abstract][Full Text] [Related]
19. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
[TBL] [Abstract][Full Text] [Related]
20. Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice.
Le Cesne A; Reichardt P
Future Oncol; 2015; 11(11 Suppl):3-14. PubMed ID: 26043310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]